奥希替尼的结构导向发现：首个获美国食品药品监督管理局批准的表皮生长因子受体T790M突变选择性抑制剂
The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.
作者信息
Butterworth Sam, Cross Darren A E, Finlay M Raymond V, Ward Richard A, Waring Michael J
机构信息
AstraZeneca , Darwin Building , 310 Cambridge Science Park , Milton Road , Cambridge , CB4 0WG , UK . Email:
出版信息
Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.
Abstract
The winners of the Malcolm Campbell Memorial Prize for 2017 discuss the structure-guided discovery of Osimertinib and the difficulties associated with discovering a new drug.
摘要
2017年马尔科姆·坎贝尔纪念奖的获得者们讨论了奥希替尼基于结构的发现过程以及发现一种新药所面临的困难。
相似文献
1
The structure-guided discovery of osimertinib: the first U.S. FDA approved mutant selective inhibitor of EGFR T790M.奥希替尼的结构导向发现：首个获美国食品药品监督管理局批准的表皮生长因子受体T790M突变选择性抑制剂
Medchemcomm. 2017 May 10;8(5):820-822. doi: 10.1039/c7md90012k. eCollection 2017 May 1.
2
Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.发现一种强效且突变选择性的 EGFR 抑制剂，可克服肺癌中 T790M 介导的耐药性。
Target Oncol. 2018 Jun;13(3):389-398. doi: 10.1007/s11523-018-0568-z.
3
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.奥希替尼用于既往接受过治疗的晚期表皮生长因子受体（EGFR）T790M 突变阳性非小细胞肺癌（NSCLC）患者：来自扩大可及项目的耐受性和诊断方法
Oncol Ther. 2018 Jun;6(1):45-58. doi: 10.1007/s40487-018-0061-y. Epub 2018 May 25.
4
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.奥希替尼治疗表皮生长因子受体T790M突变的非小细胞肺癌患者的临床特征
Cancers (Basel). 2019 Mar 15;11(3):365. doi: 10.3390/cancers11030365.
5
Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.奥希替尼治疗肺鳞状细胞癌对第一代EGFR-TKI获得性耐药的显著疗效：一例报告
World J Clin Cases. 2019 May 26;7(10):1221-1229. doi: 10.12998/wjcc.v7.i10.1221.
6
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.通过数字 droplet 聚合酶链反应（ddPCR）定量的 T790M 突变拷贝数可预测肺癌患者使用奥希替尼治疗后的疗效。
Oncotarget. 2018 Jun 15;9(46):27929-27939. doi: 10.18632/oncotarget.25332.
7
Mechanisms of resistance to osimertinib.对奥希替尼的耐药机制。
J Thorac Dis. 2020 May;12(5):2851-2858. doi: 10.21037/jtd.2019.08.30.
8
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.AME肺癌协作组关于奥希替尼在非小细胞肺癌中作用的共识。
J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61.
9
The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.表皮生长因子受体（EGFR）T790M突变状态与奥希替尼治疗非小细胞肺癌患者的临床获益相关：一项荟萃分析
J Cancer. 2020 Mar 4;11(11):3106-3113. doi: 10.7150/jca.38411. eCollection 2020.
10
Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and -C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report.奥希替尼、贝伐单抗和布加替尼联合治疗携带L858R、T790M和-C797S三重EGFR突变的肺腺癌：一例报告
Onco Targets Ther. 2018 Sep 6;11:5545-5550. doi: 10.2147/OTT.S170358. eCollection 2018.
引用本文的文献
1
Discovery and optimisation of a covalent ligand for TRIM25 and its application to targeted protein ubiquitination.TRIM25共价配体的发现与优化及其在靶向蛋白质泛素化中的应用
Chem Sci. 2025 May 12. doi: 10.1039/d5sc01540e.
2
A fragment-based electrophile-first approach to target histidine with aryl-fluorosulfates: application to hMcl-1.一种基于片段的亲电试剂优先靶向组氨酸的芳基氟硫酸盐方法：应用于人类髓细胞白血病-1蛋白
Res Sq. 2025 Mar 26:rs.3.rs-6214862. doi: 10.21203/rs.3.rs-6214862/v1.
3
Morita-Baylis-Hillman Adduct Chemistry as a Tool for the Design of Lysine-Targeted Covalent Ligands.森田-贝利斯-希尔曼加合物化学作为设计靶向赖氨酸的共价配体的工具
ACS Med Chem Lett. 2025 Feb 28;16(3):397-405. doi: 10.1021/acsmedchemlett.4c00479. eCollection 2025 Mar 13.
4
Covalent Proximity Inducers.共价接近诱导剂
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.
5
Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.胃肠道间质瘤的现有耐药机制和治疗选择：总结与更新。
Curr Treat Options Oncol. 2024 Nov;25(11):1390-1405. doi: 10.1007/s11864-024-01272-7. Epub 2024 Oct 23.
6
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53.评估多样化弹头共价文库（CovLib）与 JNK3、USP7 或 p53 的结合。
Drug Des Devel Ther. 2024 Jul 1;18:2653-2679. doi: 10.2147/DDDT.S466829. eCollection 2024.
7
Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.乙烯基吡啶作为一种靶向表皮生长因子受体（EGFR）中C797的可调节共价弹头。
ACS Med Chem Lett. 2024 Apr 5;15(5):583-589. doi: 10.1021/acsmedchemlett.3c00425. eCollection 2024 May 9.
8
Recent Development in the Search for Epidermal Growth Factor Receptor (EGFR) Inhibitors based on the Indole Pharmacophore.基于吲哚药效团寻找表皮生长因子受体（EGFR）抑制剂的最新进展
Curr Top Med Chem. 2024;24(7):581-613. doi: 10.2174/0115680266264206231020111820.
9
Development and Assessment of 1,5-Diarylpyrazole/Oxime Hybrids Targeting EGFR and JNK-2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation.开发和评估 1,5-二芳基吡唑/肟杂合体作为针对 EGFR 和 JNK-2 的抗增殖剂：通过合成、分子对接和评估的综合研究。
Molecules. 2023 Sep 8;28(18):6521. doi: 10.3390/molecules28186521.
10
Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.新型吲哚衍生物的合成及其作为双重 EGFR/SRC 激酶抑制剂的抗癌活性。
Curr Med Chem. 2024;31(24):3798-3817. doi: 10.2174/0929867330666230626143911.
本文引用的文献
1
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
2
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.发现一种有效的、选择性的 EGFR 抑制剂（AZD9291），对敏感突变和 T790M 耐药突变均有效，并且能避免野生型受体的影响。
J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.
3
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.AZD9291是一种不可逆的表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKI），可克服T790M介导的肺癌对EGFR抑制剂的耐药性。
Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.
4
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).基于结构和反应性的表皮生长因子受体（EGFR）激活和守门突变形式的共价抑制剂的开发。
J Med Chem. 2013 Sep 12;56(17):7025-48. doi: 10.1021/jm400822z. Epub 2013 Aug 30.
Zotero 插件